EGFR and lung carcinoma: Genetic abnormalities observed in lung cancer are specific to the subtype, with EGFR and KRAS mutations and increased CD44 and EGFR protein expression commonly observed in NSCLCs versus MYC amplification, TP53 and RB1 mutations, and increased BCL2 and c-KIT protein expression observed in SCLCs (98, 99).